Prospects for the use of statins in the treatment of neurofibromatosis type 1

• Published in: Uspehi molekulârnoj onkologii Vol. 9; no. 3; pp. 15 - 23
• Main Author: Mustafin, R. N.
• Format: Journal Article
• Language: English; Russian
• Published: ABV-press 07.10.2022
• Subjects: cholesterol; malignant neoplasms; neurofibromatosis type 1; neurofibromin; oncosuppressor; proto-oncogenes; statins; tumors
• ISSN: 2313-805X; 2413-3787
• DOI: 10.17650/2313-805X-2022-9-3-15-23

Neurofibromatosis type 1 is caused by a germline mutation in the NF1 gene encoding the tumor suppressor neurofibromin. Deficiency of this protein causes hyperactivation of Ras proto-oncogenes. This leads to the development of tumors. Ras proteins undergo prenylation, which is inhibited by inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Therefore, statins can be proposed as anticancer drugs in the complex treatment of neurofibromatosis type 1. Clinical studies have proven the effectiveness of statins in the treatment of sporadic malignant neoplasms, in the pathogenesis of which mutations in the NF1 gene play an important role. Various pathways of the influence of these drugs on the development of tumors are described, including the activation of autophagy, ferroptosis, suppression of proliferation, stimulation of antitumor immunity, and effects on the microenvironment of neoplasms. Data on the effect of statins on the development and progression of neurofibromas in patients with neurofibromatosis type 1 are not presented in the scientific literature. However, it was found that statins enhance the effect of anticancer drugs, the use of which in monotherapy against malignant neoplasms associated with neurofibromatosis is ineffective. In this regard, despite the inefficiency of statins in cognitive disorders in patients with neurofibromatosis type 1, the introduction of these drugs into clinical practice in combination with other drugs could provide a pleiotropic effect, affect various links in the pathogenesis of the disease.